BioWorld

Sep. 7, 2007

Faster Knockout Identification By Building A Better Haystack

Proteon Financing Gets $12M To Put Vasodilator Into Clinic

Respiratory Disease Firm Pearl Raises $15.5M In First Financing

Formed last year to use particle technologies licensed from Nektar Therapeutics Inc. for respiratory drug development, start-up Pearl Therapeutics Inc. pulled in $15.5 million in its first venture-backed financing round. (BioWorld Today) Read More

Waxman Says Any Biosimilar Pathway 'Must Be Rigorous'

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...

BioWorld

Sep. 7, 2007

Faster Knockout Identification By Building A Better Haystack

Proteon Financing Gets $12M To Put Vasodilator Into Clinic

Other News To Note

Clinic Roundup

Respiratory Disease Firm Pearl Raises $15.5M In First Financing

Waxman Says Any Biosimilar Pathway 'Must Be Rigorous'

Today's news in brief

Celia trial: data strong, analysts skeptical

News in brief

Voyager’s gene therapy reduces tau levels in AD models

GABA signaling linked to immune resistance in some tumors